RealSeq Biosciences developed the RiboMarker platform to realize the potential of RNA fragmentomics. With RiboMarker, you can discover RNA biomarkers that have never been seen before and unlock a new realm of next-generation analytes for a broad array of diagnostics applications.

RNA biomarkers are highly informative markers of disease, disease progression, and health in samples ranging from oncology, to infectious disease, and AgBio. These data-rich biomarkers can be used to determine not only whether a patient or agricultural sample has a disease, but also the state of the disease’s progression. For example, RNA biomarkers can show the dissemination of an infection from the primary site throughout the body, residual disease, or possibly even disease termination.

How RiboMarker Advances Diagnostics

Library Construction
RiboMarker novel method for preparing RNA sequencing libraries nearly eliminates incorporation bias in Next-Generation-Sequencing (NGS). This technology solves the problem of commonly used sequencing library preparations that lead to underdetection of RNA fragments, many miRNAs, and other small RNAs, some by as much as 10,000-fold.

Next-Generation Sequencing
By overcoming under-representation in library preparation, RiboMarker can detect the >90% of cfRNA that current methods cannot see. Leveraging NGS, we can accurately quantify the RNA fragmentome to develop an understanding of their biology and potential as biomarkers for therapeutic targets.

AI Bioinformatics Models
RiboMarker’s approach can measure multiple biomarkers in a single experiment. Doing so required to develop proprietary AI models that can analyze the wealth of RNA fragmentomics data and illuminate information like degradation, splicing, mutations in transcripts, and base modifications.

DOWNLOAD THE BROCHURE

TEMA RICERCA provides a trial offer on the first purchase for all clients!

Contact us at the e-mail: commerciale@temaricerca.com for the promo quote.

The promo is valid until mid-July 2025.